U.S. Insights: Trends in At-Risk Generic Drug Launches (2017 - 2024)

In this report, we analyzed 27 brand drugs that faced a first-time at-risk generic drug launch from January 2017 through June 2024.

Key findings include:

- $25.7B in peak gross sales across these brand drugs, with Copaxone ($5.1B) and Tecfidera ($3.9B) leading in peak sales.

- 51 at-risk launches from 29 different generic manufacturers

- Potential at-risk launches: 7 upcoming opportunities represented by brand drugs totaling $13.6B in peak sales, with MSN leading the pipeline.

Stay informed on the evolving landscape of at-risk launches and potential opportunities in the generic market by reading the full report.

Content on this site is proprietary to IPD Analytics. By receiving this sample you are agreeing to refrain from any unauthorized use, including uploading or inputting into AI tools or large language models for any purpose, is strictly prohibited.